San Diego-based Cypher Genomics has been offering human genome interpretation software. The company's 14 employees will join Human Longevity.
The partners will use Cypher's software to diagnose rare diseases in the Clinic's unique patient population, which includes Amish and Mennonite patients.
With funding from CurePSP, the collaborators will investigate the genetic causes of the disease, which affects a patients' speech, mobility, balance, and other abilities.
The updated Mantis provides researchers a tool for the automated interpretation of cancer-related somatic variants, including variants of unknown significance.
The BeHEARD competition will award more than $600,000 worth of technology products and services for rare disease research projects.
Sequenom will use Cypher's genome interpretation technology, Mantis, to analyze clinically relevant fetal sub-chromosomal variants detected in maternal blood.
Cypher Genomics said this week that it is offering trial access to Mantis, its genome interpretation technology through a newly launched program called Mantis 5-for-5.
Rubicon Genomics has hired Karl Hecker as vice president of product development. Previously, he was a principal scientist at HTG Molecular Diagnostics. He has also held positions at Quidel, PerkinElmer, Invitrogen, and Transgenomic.
Maverix Biomics has added Jim Bristow to its scientific advisory board.
Cypher Genomics has appointed Adam Simpson as president and chief operating officer.
The New York Times and ProPublica look into the close relationship between a startup and Memorial Sloan Kettering Cancer Center.
Yahoo News reports millions of dollars are being transferred from NIH, CDC, and other programs to pay for the housing of detained undocumented immigrant children.
In Science this week: in vitro generation of human reproductive cells, and more.
Researchers gave a handful of octopuses MDMA to find that they too act more social on the drug, Gizmodo reports.